Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Clin Cancer Res. 2014 Apr 11;20(12):3319–3327. doi: 10.1158/1078-0432.CCR-14-0069

Table 3.

Association between the LCS6-variant and DFS stratified by KRAS, BRAF, and MMR status

HR 95% CI P-value
KRAS MUTATION STATUS
  LCS6 TT, KRAS WT (n=1479) 0.73 0.62 to 0.86 0.002
  LCS6 TT, KRAS MUTANT (n=839) Ref Ref Ref
  LCS6 GT/GG, KRAS WT (n=269) 0.73 0.55 to 0.96 0.025
  LCS6 GT/GG, KRAS MUTANT (n=150) 0.83 0.59 to 1.18 0.304
BRAF MUTATION STATUS
  LCS6 TT, BRAF WT (n=1984) 1.18 0.93 to 1.51 0.17
  LCS6 TT, BRAF MUTANT (n=279) 1.47 1.08 to 2.00 0.015
  LCS6 GT/GG, BRAF WT (n=354) Ref Ref Ref
  LCS6 GT/GG, BRAF MUTANT (n=58) 1.81 1.13 to 2.91 0.015
MMR STATUS
  LCS6 TT, pMMR (n=2056) 1.09 0.61 to 1.92 0.78
  LCS6 TT, dMMR (n=265) 1.13 0.61 to 2.08 0.70
  LCS6 GT/GG, pMMR (n=375) 1.03 0.56 to 1.88 0.93
  LCS6 GT/GG, dMMR (n=45) Ref Ref Ref